Top in allergy/asthma: Vitamin D reduces wheezing; update on urticaria after vaccination
Click Here to Manage Email Alerts
A recent study showed that vitamin D supplementation during pregnancy has a protective effect on the respiratory health of children — specifically, it reduced wheezing.
Researchers said the benefits are likely due to specific alterations to the mother’s metabolism. A metabolome enriched with sphingomyelins was associated with a decreased risk for recurrent wheeze and wheeze exacerbations in children, they wrote, adding that childhood asthma prevention strategies may consider therapies that target the maternal sphingomyelin metabolism.
It was the top story in allergy/asthma last week.
Another top story was about an international, observational study of 2,769 adults with chronic urticaria, finding that 9% experienced exacerbations after COVID-19 vaccination.
Read these and more top stories in allergy/asthma below:
Vitamin D supplementation during pregnancy has positive impact on childhood wheeze
The benefits of gestational exposure to vitamin D for respiratory health in children is characterized by specific alterations to the mother’s metabolism, according to a study published in The Journal of Allergy and Clinical Immunology. Read more.
Exacerbations follow COVID-19 vaccination in minority of patients with chronic urticaria
A minority of patients with chronic urticaria experienced exacerbations after COVID-19 vaccination, with rare systemic reactions, according to a study published in The Journal of Allergy and Clinical Immunology. Read more.
Challenges remain in diagnosing, treating skin of color with atopic dermatitis
Physicians should mind variations in atopic dermatitis presentation among patients of different races, a speaker said a meeting. Read more.
Peanut oral immunotherapy may be safe, effective for infants
Oral immunotherapy for peanut allergy was safe and effective for infants, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice. Read more.
Targeting IL-18 may improve treatment for eosinophilic esophagitis
Inhibiting the NLRP3 pathway and the release of IL-18 may prevent the development of eosinophilic esophagitis, according to a study published in Nature’s Communications Biology. Read more.